

Amnon Peled

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10537081/publications.pdf>

Version: 2024-02-01

102
papers

9,166
citations

57631

44
h-index

45213

90
g-index

102
all docs

102
docs citations

102
times ranked

10774
citing authors

#	ARTICLE	IF	CITATIONS
1	G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. <i>Nature Immunology</i> , 2002, 3, 687-694.	7.0	1,215
2	The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. <i>Blood</i> , 2000, 95, 3289-3296.	0.6	685
3	Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. <i>Journal of Clinical Investigation</i> , 2000, 106, 1331-1339.	3.9	516
4	The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flow. <i>Journal of Clinical Investigation</i> , 1999, 104, 1199-1211.	3.9	479
5	CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. <i>Blood</i> , 2004, 103, 2981-2989.	0.6	466
6	Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. <i>FASEB Journal</i> , 2004, 18, 1240-1242.	0.2	372
7	CXCL12 expression by invasive trophoblasts induces the specific migration of CD16 ⁺ human natural killer cells. <i>Blood</i> , 2003, 102, 1569-1577.	0.6	326
8	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
9	Subsecond Induction of β 4 Integrin Clustering by Immobilized Chemokines Stimulates Leukocyte Tethering and Rolling on Endothelial Vascular Cell Adhesion Molecule 1 under Flow Conditions. <i>Journal of Experimental Medicine</i> , 2000, 192, 495-506.	4.2	296
10	Rapid and efficient homing of human CD34 ⁺ CD38 ^{low} /CXCR4 ⁺ stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2mnull mice. <i>Blood</i> , 2001, 97, 3283-3291.	0.6	283
11	Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. <i>Journal of Clinical Investigation</i> , 2014, 124, 3121-3128.	3.9	224
12	Critical Involvement of the Chemotactic Axis CXCR4/Stromal Cell-Derived Factor-1 in the Inflammatory Component of Allergic Airway Disease. <i>Journal of Immunology</i> , 2000, 165, 499-508.	0.4	181
13	β 2 Microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function. <i>Blood</i> , 2000, 95, 3102-3105.	0.6	175
14	Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. <i>Experimental Hematology</i> , 2012, 40, 342-355.e1.	0.2	168
15	A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. <i>EMBO Journal</i> , 2006, 25, 4628-4637.	3.5	149
16	Human CD34 ⁺ CXCR4 ⁺ sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. <i>Blood</i> , 2002, 100, 2778-2786.	0.6	147
17	Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. <i>Blood</i> , 2004, 103, 2900-2907.	0.6	136
18	Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. <i>Oncotarget</i> , 2014, 5, 11283-11296.	0.8	130

#	ARTICLE	IF	CITATIONS
19	Atypical PKC- ζ regulates SDF-1 α -mediated migration and development of human CD34+ progenitor cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 168-176.	3.9	127
20	The Chemokine CXCL16 and Its Receptor, CXCR6, as Markers and Promoters of Inflammation-Associated Cancers. <i>PLoS ONE</i> , 2009, 4, e6695.	1.1	125
21	Involvement of the CXCL12/CXCR4 Pathway in the Recovery of Skin Following Burns. <i>Journal of Investigative Dermatology</i> , 2006, 126, 468-476.	0.3	120
22	Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. <i>European Journal of Immunology</i> , 2004, 34, 1164-1174.	1.6	104
23	Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. <i>Blood</i> , 2003, 102, 1951-1958.	0.6	103
24	Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia. <i>Theranostics</i> , 2013, 3, 34-39.	4.6	94
25	Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003. <i>Stem Cells</i> , 2007, 25, 2158-2166.	1.4	93
26	CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. <i>Experimental Hematology</i> , 2011, 39, 282-292.	0.2	86
27	IFN- γ Treatment at Early Stages of Influenza Virus Infection Protects Mice from Death in a NK Cell-Dependent Manner. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 439-449.	0.5	83
28	IFN- γ Acts on T Cells to Induce NK Cell Mobilization and Accumulation in Target Organs. <i>Journal of Immunology</i> , 2006, 176, 4716-4729.	0.4	82
29	Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 621-630.	1.1	81
30	CD4+CXCR4 ^{high} CD69+ T Cells Accumulate in Lung Adenocarcinoma. <i>Journal of Immunology</i> , 2006, 177, 6983-6990.	0.4	79
31	Development of novel CXCR4-based therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 341-353.	1.9	78
32	The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 469-479.	3.2	76
33	Immature Leukemic CD34+CXCR4+ Cells from CML Patients Have Lower Integrin-Dependent Migration and Adhesion in Response to the Chemokine SDF-1. <i>Stem Cells</i> , 2002, 20, 259-266.	1.4	73
34	Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: Role in non-small cell lung cancer tumor proliferation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, 1503-1512.	0.4	70
35	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. <i>Cytokine</i> , 2018, 109, 11-16.	1.4	70
36	Chemokines in hepatitis C virus infection: Pathogenesis, prognosis and therapeutics. <i>Cytokine</i> , 2007, 39, 50-62.	1.4	66

#	ARTICLE	IF	CITATIONS
37	Interaction between CXCR4 and CCL20 Pathways Regulates Tumor Growth. <i>PLoS ONE</i> , 2009, 4, e5125.	1.1	66
38	Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. <i>Hepatology</i> , 2013, 58, 1021-1030.	3.6	65
39	Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease Progression. <i>PLoS ONE</i> , 2011, 6, e24856.	1.1	65
40	Role of wild type p53 in the G2 phase: regulation of the γ irradiation-induced delay and DNA repair. <i>Oncogene</i> , 1997, 15, 2597-2607.	2.6	62
41	Atypical PKC- η regulates SDF-1-mediated migration and development of human CD34+ progenitor cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 168-176.	3.9	61
42	In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 1167-1175.e1.	0.4	60
43	Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1155-1169.	1.9	59
44	Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140. <i>Clinical Cancer Research</i> , 2013, 19, 3495-3507.	3.2	56
45	Chemokine Receptor Expression in Peripheral Blood Monocytes from Patients with Neovascular Age-Related Macular Degeneration. , 2012, 53, 5292.		50
46	Recruited Macrophages Control Dissemination of Group A <i>Streptococcus</i> from Infected Soft Tissues. <i>Journal of Immunology</i> , 2011, 187, 6022-6031.	0.4	47
47	CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways. <i>Cancer Research</i> , 2018, 78, 1471-1483.	0.4	47
48	Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. <i>Blood</i> , 2006, 107, 3821-3831.	0.6	43
49	Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers. <i>Clinical Cancer Research</i> , 2017, 23, 6790-6801.	3.2	43
50	Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. <i>Hepatology</i> , 2013, 58, 192-204.	3.6	40
51	Improvement of CXCR4 tracer specificity for PET imaging. <i>Journal of Controlled Release</i> , 2012, 157, 216-223.	4.8	37
52	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	3.2	37
53	Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. <i>Hepatology</i> , 2017, 65, 1600-1611.	3.6	28
54	The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 1733-1747.	3.2	28

#	ARTICLE	IF	CITATIONS
55	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 425-436.	1.2	27
56	Proangiogenic characteristics of activated macrophages from patients with age-related macular degeneration. <i>Neurobiology of Aging</i> , 2017, 51, 71-82.	1.5	27
57	Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions. <i>Cytokine</i> , 2011, 54, 249-257.	1.4	26
58	The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. <i>Blood</i> , 2000, 95, 3289-3296.	0.6	26
59	Matrix metalloproteinase 12 promotes tumor propagation in the lung. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2164-2175.e1.	0.4	25
60	Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. <i>Journal of Hematology and Oncology</i> , 2020, 13, 158.	6.9	24
61	Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. <i>European Journal of Immunology</i> , 2004, 34, 1333-1341.	1.6	23
62	Chemokines and chemokine receptors in stem cell circulation. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6820.	3.0	23
63	Focal liver necrosis appears early after partial hepatectomy and is dependent on T cells and antigen delivery from the gut. <i>Liver International</i> , 2009, 29, 1273-1284.	1.9	21
64	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. <i>Cancer</i> , 2021, 127, 1246-1259.	2.0	21
65	Cycling G1 CD34+/CD38+ Cells Potentiate the Motility and Engraftment of Quiescent G0 CD34+/CD38 ^{low} Severe Combined Immunodeficiency Repopulating Cells. <i>Stem Cells</i> , 2005, 23, 561-574.	1.4	16
66	CD74 is a regulator of hematopoietic stem cell maintenance. <i>PLoS Biology</i> , 2021, 19, e3001121.	2.6	15
67	In the Hunt for Therapeutic Targets: Mimicking the Growth, Metastasis, and Stromal Associations of Early-Stage Lung Cancer Using a Novel Orthotopic Animal Model. <i>Journal of Thoracic Oncology</i> , 2015, 10, 46-58.	0.5	12
68	The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. <i>Biochemical Pharmacology</i> , 2019, 168, 412-428.	2.0	12
69	Multiple Roles of IL6 in Hepatic Injury, Steatosis, and Senescence Aggregate to Suppress Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 4766-4777.	0.4	12
70	DSP107 combines inhibition of CD47/SIRP α axis with activation of 4-1BB to trigger anticancer immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 97.	3.5	12
71	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014, 124, 950-950.	0.6	11
72	BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation. <i>Blood</i> , 2010, 116, 2260-2260.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Neor6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2008, 1780, 914-920.	1.1	8
74	CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.. <i>Journal of Clinical Oncology</i> , 2018, 36, 73-73.	0.8	8
75	Nicotinamide Modulates Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells Cultured with Cytokines and Promotes Their Homing and Engraftment in SCID Mice.. <i>Blood</i> , 2006, 108, 725-725.	0.6	7
76	Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis. <i>Clinical Immunology</i> , 2017, 183, 316-324.	1.4	6
77	Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-Applicable Method for NK Expansion. <i>Blood</i> , 2017, 130, 657-657.	0.6	6
78	Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production. <i>British Journal of Haematology</i> , 2013, 163, 248-259.	1.2	5
79	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. <i>Blood</i> , 2013, 122, 3939-3939.	0.6	5
80	Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	4
81	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. <i>Journal of Clinical Oncology</i> , 2018, 36, 88-88.	0.8	4
82	DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses. <i>Blood</i> , 2020, 136, 19-20.	0.6	4
83	BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models. <i>Blood</i> , 2018, 132, 1451-1451.	0.6	3
84	Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14544-e14544.	0.8	3
85	Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance. <i>Bone Marrow Transplantation</i> , 2020, 55, 1305-1316.	1.3	3
86	Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	2
87	Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential. <i>Blood</i> , 2019, 134, 3718-3718.	0.6	1
88	Anti-Leukemia and Multiple Myeloma Selective Activity of CXCR4 Antagonist 4F-Benzoyl-TN14003 Involves Apoptotic Death Pathway.. <i>Blood</i> , 2009, 114, 3857-3857.	0.6	1
89	The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38 ^{hi} CD45RA ^{hi} CD90 ⁺ CD49f ⁺ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity. <i>Blood</i> , 2017, 130, 660-660.	0.6	1
90	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-276.	0.8	1

#	ARTICLE	IF	CITATIONS
91	CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death. <i>Blood</i> , 2019, 134, 2745-2745.	0.6	1
92	162â€¦Nicotinamide rejuvenates ex-vivo expanded natural killer cells and enhances their tumor killing capacity. , 2021, 9, A172-A172.		1
93	Multiple Myeloma and Microenvironment Formation: The Role of CXCR4/CXCL12 Chemokine Pathway. <i>Blood</i> , 2010, 116, 2962-2962.	0.6	0
94	Role of the CXCR4/CXCL12 Axis in Hematopoietic Stem Cell Trafficking. , 2012, , 71-85.		0
95	Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML in Vitro and in Vivo. <i>Blood</i> , 2012, 120, 3735-3735.	0.6	0
96	S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways. <i>Blood</i> , 2014, 124, 4707-4707.	0.6	0
97	The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression. <i>Blood</i> , 2016, 128, 767-767.	0.6	0
98	The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis. <i>Blood</i> , 2016, 128, 891-891.	0.6	0
99	Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma. <i>Blood</i> , 2017, 130, 804-804.	0.6	0
100	Brief Ex Vivo Incubation with Fas Ligand Selectively Depletes Alloreactive T Cells and Antigen Presenting Cells from Stem Cell Grafts. <i>Blood</i> , 2018, 132, 2033-2033.	0.6	0
101	Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs). <i>Blood</i> , 2018, 132, 1366-1366.	0.6	0
102	790â€¦DSP502 â€” A novel approach for targeting TIGIT and PD1 pathways for cancer immunotherapy. , 2021, 9, A825-A825.		0